跳至主要内容
临床试验/NCT05028985
NCT05028985招募中不适用

A Cohort Study of Early Chronic Obstructive Pulmonary Disease for China Pulmonary Health Study Stage II

China-Japan Friendship Hospital6 个研究点 分布在 1 个国家目标入组 400 人开始时间: 2021年1月1日最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
发起方
入组人数
400
试验地点
6
主要终点
FEV1 annual decline in clinical practice

研究概览

简要总结

Discovery of the pathogenesis and targets in the progression of early chronic obstructive pulmonary disease

详细描述

This project is aimed to investigate and explore the heterogeneity during the progression of Chronic Obstructive Pulmonary Disease (COPD) in the early stage, utilizing the large-scale population cohort databases (including "China Pulmonary Health study", "The Cohort Study for Chronic Obstructive Pulmonary Disease in China" and "Acute Exacerbation of COPD Patient Registry in China" ), biological sample libraries(including blood, sputum, expiratory air, bronchoalveolar lavage fluid(BALF), and lung tissue from COPD patients with different stages and phenotypes), and multi-omics sequencing (including scRNA-seq, metabolomics, proteomics, and metagenome). We propose to establish a new standard for COPD stages and subtypes. By analyzing and mining the multi-omics data, it is expected to illustrate the association between clinical phenotype and molecular, cellular and tissue heterogeneities, thus reveal biomarkers related to the progression, clinical phenotypes, and prognosis of early-stage COPD disease.In addition, we will construct different types and stages of COPD animal models for further mechanism studies, such as the different pathogenic factors, innate and adaptive immunity, and the airway microbial ecosystem, so that we can discovered more potential therapeutic target for early-stage COPD. This project can bring a new insight and scientific evidence for COPD treatment.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 50 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • younger than 50 years
  • smoking more than 10 pack-years
  • early airflow limitation(post-bronchodilator FEV1/FVC< lower limit of normal)

排除标准

  • other respiratory diseases
  • mental illness

结局指标

主要结局

FEV1 annual decline in clinical practice

时间窗: 2021.1-2024.12

FEV1 measured by portable spirometry can reflect the progression of early COPD.

次要结局

  • dyspnea symptoms(2021.1-2024.12)
  • frequency of COPD acute exacerbation(2021.1-2024.12)
  • chest imaging changes(2021.1-2024.12)
  • systemic complications(2021.1-2024.12)

研究者

发起方
China-Japan Friendship Hospital
申办方类型
Other
责任方
Principal Investigator
主要研究者

Chen Wang

Study Chair

China-Japan Friendship Hospital

研究点 (6)

Loading locations...

相似试验